Taken together, our results provide novel mechanistic insights for a better understanding of the role of METTL3 in BC cell resistance to ADR via the functional axis of miR-221-3p/HIPK2/Che-1, offering a novel therapeutic strategy against the development and progression of BC. This evidence concerns the gene METTL3 and breast cancer.